<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Clarity with
Crown

Recognize your next clinical candidate when you see it.

Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.

Magnify your
insights

Understand the mechanisms of disease.

Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.

Begin with the
end insight

Connecting science to patients.

We help our clients solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease by answering some of the most challenging questions about human biology.

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

August 2, 2021

In vivo preclinical models for immune-mediated inflammatory disease drug development

In this blog we will explore immune-mediated inflammatory diseases (IMIDs)—which represent a diverse group of conditions characterized by an excessive and/or inappropriate immune response. Interest in IMIDs has grown rapidly in recent years, largely fueled by the view that IMIDs share common inflammatory pathways, and therefore, there...

Read More

July 5, 2021

Preclinical Models for Bispecific T Cell Engager Development

Last month we hosted a webinar with Dr. Ludovic Bourré, Senior Director of Scientific Engagement...

Read More

June 1, 2021

Ask the Expert: Organoid and Immune Cell Co-Cultures

Dr Yujun Huang, Senior Director Immuno-Oncology at CrownBio, answers the most popular questions...

Read More

May 4, 2021

For the Children: Advancing the Cause of Pediatric Cancer Research

Why are cancer treatments for children lagging behind the latest advancements in clinical...

Read More

April 1, 2021

Expanding the Horizon of Antibody-Drug Conjugates for Cancer Treatment

This post explores the fast-expanding topic of antibody-drug conjugates (ADCs), including those...

Read More

Upcoming Events


July 15, 2021

Advancing Authentication: Next Generation Technology for Cell Line and Biosample Verification


September 21-23, 2021

6th Annual PREDiCT: 3D Tissue Models Summit

The Colonnade Boston